Thrombosis of unusual venous sites encompasses a large part of consultative hematology and is encountered routinely by practicing hematologists. Contrary to the more commonly encountered lower extremity venous thrombosis and common cardiovascular disorders, the various thromboses outlined in this review have unique presentations, pathophysiology, workup, and treatments that all hematologists should be aware of. This review attempts to outline the most up to date literature on cerebral, retinal, upper extremity, hepatic, portal, splenic, mesenteric, and renal vein thrombosis, focusing on the incidence, pathophysiology, provoking factors, and current recommended treatments for each type of unusual thrombosis to provide a useful and practical review for the hematologist.
| INTRODUC TI ON
Thrombosis of the deep veins of the lower extremities is a common, well-studied illness, routinely encountered by many medical and surgical disciplines. Due to its high prevalence in multiple clinical settings, many physicians feel comfortable with the routine diagnosis and management of straightforward venous thromboembolism (VTE). Less commonly, thrombosis can occur at unusual venous sites including the veins within the central nervous system, abdomen, or within intra-abdominal organs. Thrombosis in these more unusual sites has significantly different and more obscure provoking factors and in some instances heralds the onset of other occult illnesses, often compelling the physician to consider a unique workup and treatment plan.
While understudied, the current body of knowledge on these rare thromboses suggests that unique local and systemic factors are often at play, specific to each site of thrombosis. In this review, we have outlined the epidemiology, common provoking entities, pathophysiology, and treatment (Table 1) in these admittedly understudied illnesses in an attempt to make a practical review for the hematologist.
| CEREB R AL VEIN THROMBOS IS
Cerebral venous thrombosis (CVT), including thrombosis of cerebral veins and major dural sinuses, can present with a variety of symptoms including headache, focal neurologic deficits, seizures, and progression to infarction or hemorrhage. 1, 2 CVT is a rare entity accounting for <1% of all strokes. 3 It is three times more common in women as compared to men, occurring at a much younger age on average in women (34 years vs 42 years). 4 In CVT, 85% of patients will have an identifiable risk factor, the most common of which are estrogen-containing oral contraceptive use or pregnancy. 2 Other rare causes include acquired thrombophilia, vasculitis, myeloproliferative neoplasms (MPNs), chronic inflammatory disorders, or local factors such as infection, malignancy, trauma, or surgery. 2 Both cerebral vein and cerebral sinus thrombosis lead to increased venous pressure causing disruption of the blood-brain barrier and subsequent vasogenic and cytotoxic edema. Obstruction of cerebral sinuses may also result in decreased cerebrospinal fluid absorption leading to increased intracranial pressure-worsening venular hypertension and contributing to parenchymal hemorrhage.
1
Anticoagulation should be started immediately in patients with CVT, even in patients with CVT that has progressed to hemorrhage. Two studies compared outcomes in patients treated with anticoagulation vs placebo, one of which was halted early due to benefit in the anticoagulation arm. 5, 6 Meta-analysis of the two trials found a trend toward decreased mortality in the anticoagulation arms which did not reach significance, likely due to the small size of the studies, and noted that no new intracranial hemorrhages occurred in any patient. 7 In patients who present with CVT with secondary intracranial hemorrhage, evidence still suggests a benefit to anticoagulation. 8 Systematic review of multiple studies found that early partial or complete recanalization occurs in two-thirds of patients treated with anticoagulation, and approximately 90% of surviving patients recover fully or with only minor deficits. 9 Alternative interventions exist including catheter-directed thrombolysis, mechanical thrombectomy, or surgery; however, data are limited on their use, and these measures are usually reserved for patients who deteriorate despite systemic anticoagulation. 8 The recurrence rate for patients with cerebral vein thrombosis is low, especially if there was a provoking factor in the initial thrombosis. 10 For thrombosis related to estrogen or other provoking etiologies three months may suffice while for idiopathic thrombosis expert recommendations vary from six months to a year.
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| RE TINAL VEIN THROMBOS IS
Retinal vein occlusion (RVO) is a sight-threatening malady often presenting with acute painless unilateral vision loss, although occlusion of a branch retinal vein may be asymptomatic, or present with double vision, or hemianopsia. 12 Large epidemiologic studies have noted a prevalence of retinal vein occlusion between 0.5% in middle-aged adults to as high as 4.6% in patients over 80 years old, suggesting that in any given year, several million adults are affected by this disease.
13
Unlike traditional venous thrombosis, the risk factors for RVO mimic those of small vessel arterial disease. Hypertension, diabetes mellitus, smoking, and obesity have all been shown to increase the risk of RVO while increased physical activity, alcohol use, and increase HDL have been suggested to be protective. 14, 15 Openangle glaucoma and increased blood viscosity also appear to be risk factors. 16, 17 The pathogenesis of RVO is not well understood. 
28,29
Unprovoked upper extremity thrombosis is exceedingly rare, occurring in only 2 per 100 000 patients per year. 27, 30 Unprovoked cases are often secondary to "effort" thrombosis, also known as Paget-Schroetter syndrome. 27, 31 More prevalent in younger patients, Paget-Schroetter syndrome is thought to be secondary to a combination of vessel micro trauma and local muscle hypertrophy from exercise that occurs in patients predisposed to venous scaring or thoracic outlet syndrome. 27, 31 A preceding history of strenuous upper extremity use or exercise is often noted.
27,31
For catheter-associated thrombosis, current guidelines recommend keeping the catheter in place if it is needed as long as anticoagulation is initiated and continuing anticoagulation for 3 months after its removal. 32 Given the high incidence of asymptomatic or minimally symptomatic thrombosis associated with peripherally inserted central catheters (PICCs) and the relatively low rates of pulmonary embolism (~ 5%), 33 treatment with PICC removal alone may be a reasonable strategy. Local thrombolysis/surgery for severe cases leading to organ dysfunction.
The use of prophylactic anticoagulation in patients with nephrotic syndrome is controversial. In patients who develop thrombosis, anticoagulation should be continued as secondary prophylaxis until the nephrotic syndrome is in remission.
MPN, myeloproliferative neoplasm; PNH, paroxysmal nocturnal hemoglobinuria; TIPS, transjugular intrahepatic portosystemic shunt; PICC, peripherally inserted central catheter.
TA B L E 1 (Continued) removal through an axillary or clavicular approach remain treatment options. 34 
| BUDD -CHIARI SYNDROME (HEPATIC VEIN THROMBOS IS)
Thrombosis of the hepatic veins (Budd-Chiari Syndrome) can result in significant morbidity including acute liver failure, encephalopathy, ascites, and portal hypertension. 35, 36 A minority of cases, approximately 20%, are asymptomatic at the time of detection. 37 The diagnosis of Budd-Chiari should be suspected in any patient with ascites and evidence of acute hepatic congestion.
Budd-Chiari syndrome is a rare disorder, with scarce epidemiological data. One of the largest cohorts of 237 European and
American patients found two-thirds were female with an average age of 35 years. 36 MPNs are reported to be the cause of 40%-50% 
Anticoagulation should be initiated immediately in patients with
Budd-Chiari syndrome, with observational data suggesting this improves outcomes as the natural history of Budd-Chiari syndrome is progressive liver failure and death. 41 There are no randomized clinical trial data to guide management, but a stepwise approach has been advocated for patients with progressive levels of liver failure which includes consideration of thrombolytic therapy, angioplasty/ stenting, placement of a transjugular intrahepatic portosystemic shunt (TIPS), surgical shunting, or lastly, liver transplantation.
40,42
Modern series that incorporate the former treatment options report a 74% five-year survival. 36 In most cases, anticoagulation should be continued indefinitely, even in asymptomatic patients, especially if an underlying thrombophilia is found.
| THROMBOS IS OF THE P ORTAL VENOUS SYS TEM
The hepatic portal vein, splenic vein, and mesenteric veins (some authors include the hepatic veins) comprise the hepatic portal venous system or "splanchnic veins." 43 Portal vein thrombosis is the most common form of splanchnic vein thrombosis accounting for 77% in a large prospective series of 604 patients, with 38% of patients having multiple splanchnic vein thromboses at presentation. 44 Splanchnic vein thrombosis is a heterogeneous disease which limits the ability to make generalized recommendations about its treatment. Many factors including the provoking etiology, the level of symptoms (which can range from asymptomatic to highly symptomatic organ failure), the bleeding risk, and the risk of thrombus propagation should be taken into consideration when treating patients with splanchnic vein thrombosis. In general, anticoagulation is warranted for symptomatic cases, while guidelines recommend no anticoagulation or at least a careful risk/ benefit analysis in patients with asymptomatic, incidentally found splanchnic vein thrombosis (not including Budd-Chiari). 11 With these generalities in mind, in the following sections, we outline specifics about each of the splanchnic veins.
| Portal vein thrombosis
Partial or completely occlusive portal vein thrombosis (PVT) is often clinically silent, but rarely can be associated with significant symptoms including new onset or worsening portal hypertension, acute gastrointestinal bleeding, decompensation of previously stable cirrhosis, or intestinal ischemia. 40, 45 Large studies of portal vein thrombosis have found a population prevalence of 1% on autopsy with the most common precipitants including cirrhosis (28%), primary hepatobiliary malignancy (23%), secondary malignancy (44%), idiopathic (14%), infectious or inflammatory abdominal processes (10%), and MPNs (3%). 46 Portal vein thrombosis is also found after abdominal surgery, especially laparoscopic splenectomy with an incidence up to 5%-10%, typically presenting with postoperative nausea, vomiting, and abdomen pain. 47 Clinically, cirrhosis is one of the most commonly associated precipitants of PVT. In cirrhotic patients, rates of portal vein thrombosis have been reported in 5%-27% of cases. 48 The development of portal vein thrombosis in cirrhosis is likely a multifactorial process brought about by decreased portal blood flow, local inflammatory factors, and clotting factor derangements inherent in cirrhosis which predispose to a prothrombotic state. 49 The incidence of portal vein thrombosis has been shown to correlate with the degree of liver impairment and occurs at different frequencies based on the etiology of cirrhosis. 50, 51 The natural history of portal vein thrombosis in cirrhotic patients is not well studied, and there are limited data on spontaneous recanalization or progression rates. A retrospective study of patients with viral-associated cirrhosis found an incidence of 28% with a spontaneous regression rate of 47%, stable disease in 45%, and progression in 7%. 52 Studies evaluating predictors of portal vein thrombosis in cirrhotic patients have shown that a portal flow rate <15 cm/s is a significant risk factor for PVT development, and have also found that cirrhotic patients who develop PVT are more likely to have worse MELD scores, lower platelets, lower albumin, and lower circulating levels of protein C, protein S, and antithrombin III. 52, 53 Recently, a large prospective study of 1243 cirrhotic patients followed on screening ultrasounds confirmed that the severity of liver disease predicts PVT development, but did not find that the development of PVT worsened liver disease severity. rates of recurrence (38.5%) have been reported with discontinuation. [58] [59] [60] [61] [62] Although studies suggest recanalization improves overall cirrhotic endpoints including portal hypertension-related bleeding, ascites, and encephalopathy, these findings did not reach significance. 62 Retrospective data from the national inpatient sample suggest that cirrhotic patients with a documented PVT had longer hospital length of stay, higher mean hospital charges, and a higher proportion of cirrhosis-related complications. 63 One study evaluating prophylaxis to prevent PVT found that the group receiving anticoagulation had significantly less likelihood of developing a PVT, developing decompensated liver failure, and a significant survival benefit. 64 Bleeding complications have generally been low, although variceal bleed prophylaxis was not used consistently. 65 At least one study noted significantly lower bleeding rates in the cirrhotic patients receiving anticoagulation compared to the control group. 59 The ideal anticoagulant choice in cirrhosis is beyond the scope of this review; however, our practice has been to use low molecular weight heparin or more recently direct oral anticoagulants (DOACs) in select patients.
66,67
| S PLENI C VEIN THROMBOS IS
Isolated splenic vein thrombosis (SVT) is often secondary to pancreatic disorders including pancreatic cancer, pseudocysts, pancreatic abscess, and especially pancreatitis, occurring in up to 22% of patients with acute pancreatitis and 12% of patients with chronic pancreatitis. 68, 69 SVT often causes left-sided or "sinistral" portal hypertension as collateral blood flows through the splenoportal and gastroepiploic systems leading to a confined venous hypertension and the development of gastric varices localized to the short gastric and left gastroepiploic veins. 70 Sinistral portal hypertension significantly increased the risk of upper gastrointestinal bleeding which was a common first presenting symptom of SVT before the routine use of CT scanning. 70 Rates of gastric varices in SVT patients range from 53% to 77%, with reported rates of clinically significant gastrointestinal bleeding ranging from 4% to 12%. 68, 70 Splenomegaly occurs in 42%-54% of SVT patients.
68
Sinistral portal hypertension can be cured with splenectomy which is the treatment of choice for patients with uncontrollable bleeding episodes. 71 There are data to suggest that patients without objective evidence of gastrointestinal bleeding may be managed expectantly. 71 No prospective trial has evaluated the safety and utility of anticoagulation in patients with SVT specifically. 
| ME S ENTERI C VEIN THROMBOS IS
While often clinically silent, approximately 5% of cases of acute mesenteric ischemia are caused by venous thrombosis. 74 The superior mesenteric vein is more commonly involved, leading to impaired drainage from the distal small bowel provoking bowel wall edema and subsequent hemorrhagic infarction. 75 Epidemiologic studies on mesenteric thrombosis are sorely lacking, but small studies have confirmed it to be a rare event, accounting for only 0.002%-0.06% of all inpatient admissions. 76 While often presenting as an extension of other splanchnic vein thrombosis, there are no large studies examining the incidence of provoking conditions associated with isolated mesenteric vein thrombosis. One study of 51 patients presenting over a 6-year period to a single institution found a detectable associated condition in 80% of patients. A total of 25% had a local process including pancreatitis, inflammatory bowel disease, or recent surgery, 24% had a malignancy, 12% had venous congestion as defined by portal hypertension, severe heart failure, or morbid obesity, and 29% were noted to have a previous or concurrent extra mesenteric thrombosis.
77
Studies specific to patients with inflammatory bowel disorders have suggested a high inherent prevalence of mesenteric vein thrombosis (26%).
78
Of the splanchnic vein thromboses, isolated occult mesenteric vein thrombosis is the least likely to be associated with malignancy or MPNs. Søgaard and colleagues examined a data set containing 126 patients with occult mesenteric vein thrombosis and found only one associated malignancy and no associated MPNs. 79 Other small series have noted about 25% of patients will have an associated intra-abdominal malignancy. 77 Small studies and case reports have suggested an increased incidence of inherited thrombophilia in patients with mesenteric vein thrombosis including activated protein C resistance, protein C and S deficiency, prothrombin gene mutation G20210A, factor V Leiden gene mutation, and antiphospholipid syndrome; however, the clinical utility and changes in management that would arise from testing for these entities should be considered on a case by case basis.
80,81
Anticoagulation should be initiated immediately for both acute and subacute mesenteric vein thrombosis. For cases with significant symptoms, IV fluids, bowel rest, decompression, nutritional support, and careful monitoring should be undertaken. Surgical interventions may be necessary in patients who have complications of mesenteric ischemia which can include catheter-directed thrombolysis, exploratory laparotomy with bowel resection as needed. 82, 83 Retrospective studies have suggested that rates of major bleeding in patients with mesenteric thrombosis on anticoagulation are low (2.6%) 84 Despite modern treatment options, 30-day mortality for mesenteric vein thrombosis remains high at a reported 20%. 83 
| RENAL VEIN THROMBOS IS
Renal vein thrombosis (RVT) may be asymptomatic, but can present acutely, with symptoms including flank pain, hematuria, nausea, vomiting, anorexia, fever, and acute renal dysfunction. 85, 86 One large cohort study of 218 individuals diagnosed with first incident RVT found malignancy (66%) and nephrotic syndrome (20%) to be the most common underlying etiologies. Among these patients, the left renal vein was implicated more often than the right (43% vs. 33%), with bilateral renal vein involvement (21%) and progression to the inferior vena cava (43%) being fairly common. 85 A large retrospective study of patients with nephrotic syndrome found a 1% annual incidence of venous thromboembolism and a 1.5% annual incidence of arterial thrombosis, with the highest incidence of thrombosis in membranous glomerulonephritis. 87 Several potential thrombosis promoting mechanisms have been suggested in nephrotic syndrome, falling into two main categories: urinary loss of anti-thrombotic clotting factors and a relative increase in prothrombotic factors. 88, 89 Nephrotic syndrome results in decreased circulating levels of antithrombin III, plasminogen, and possibly proteins C and S. 89, 90 Several prothrombotic factors including factor V, factor VIII, von Willebrand factor, fibrinogen, and plasminogen activator inhibitor are also increased. [90] [91] [92] Decreased osmotic pressure and hypoalbuminemia subsequently stimulates the synthesis of betathromboglobulin and fibrinogen in the liver, leading to increased platelet count and aggregation, increased blood viscosity, and promotion of erythrocyte aggregation. 88, 92 There is debate about the use of prophylactic anticoagulation in nephrotic patients to prevent thrombosis, stemming from a lack of controlled prospective data. 93 One prospective uncontrolled study of LMWH prophylaxis in 30 patients with nephrotic syndrome found no thrombosis on screening imaging after 12 months of therapy. 
